Palvella Therapeutics, Inc.
PVLA
NASDAQ·Healthcare·Biotechnology·Mkt cap $2.2B
$152.59
▲ +1.75%
P/E
-31.59
Mkt Cap
$2.2B
52-Wk Range
$50.82–$161.38
52-Week Range
$50.82 - $161.38
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 189.5% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
3 reasons
- Proprietary QTORIN rapamycin gel formulation with optimized bioavailability
- Advanced clinical development stage (Phase 3) in underserved rare disease markets
- Focused pipeline targeting mTOR-driven skin pathologies with validated mechanism
Bear Case
1 risk
- Low volatility (beta -0.2).
Growth
Stable outlook
Phase 3 trial completion and potential FDA approval for microcystic lymphatic malformations
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Hot
+35.5% over 3m
Quality
Loss-making
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying PVLA right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 10, 2026
AUG 4, 2026
Reported EPS of -$1.52 vs -$1.17 consensus (-29.9% surprise).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-29.9%
Revenue trend · last 8Q
—
-100%
—
—
—
—
—
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$0
$0
$0
$0
$0
$0
$0
Margins · last 8Q
No margin history available.
Wall Street consensus
3 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Stephens · May 21, 2026
vs Industry
How PVLA stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related